thus I'd pick an estimate in the middle (around 50%).
Very well, stick to that. It only means that the fall is at the half-way point. Anyway, to get back to the original subject, and to amend an earlier post of mine:
In the RMF - here - the model that inspired DewD's estimate of a potential 20% royalty settlement from Amphastar is: "the Tercica-INSM case, in which INSM paid Tercica a 20% royalty on sales" per this .... Now, knowing that the Tercica and INSM drugs were not only branded drugs, but also ORPHAN branded drugs, and you are aware that ORPHAN branded drugs typically have 90% or higher GM, don't you feel it a gross distortion that this 'example' remains in the RMF?
Market Data 
Markets 
AI
